Ignite Creation Date:
2025-12-25 @ 2:09 AM
Ignite Modification Date:
2026-03-07 @ 9:30 PM
Study NCT ID:
NCT02171260
Status:
COMPLETED
Last Update Posted:
2019-01-15
First Post:
2014-06-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-07-31
Start Date Type:
ACTUAL
Primary Completion Date:
2016-01-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-01-28
Completion Date Type:
ACTUAL
First Submit Date:
2014-06-18
First Submit QC Date:
None
Study First Post Date:
2014-06-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-06-18
Results First Submit QC Date:
None
Results First Post Date:
2018-12-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-01-02
Last Update Post Date:
2019-01-15
Last Update Post Date Type:
ACTUAL